Kai Rejeski (@KRejeski) / X

Kai Rejeski

561 posts

Kai Rejeski

@KRejeski

Research Group Leader @LMU | Visiting Investigator @MSKCC | Interested in novel biomarkers and modelling CAR-T toxicity and response | 🇩🇪🇺🇸

Joined August 2019

Pinned
Kai Rejeski
@KRejeski
Jul 8, 2024
🚨 hot off the press 🚨 A (perhaps) underestimated aspect of CAR T-cell therapy: non-relapse mortality. Check out our new meta-analysis on this clinically relevant topic - out today in @NatureMedicine ! nature.com/articles/s4159… Let’s take a deeper dive! Start 🧵
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
From nature.com
50K
Kai Rejeski
@KRejeski
Jul 2, 2022
Really excited that our paper on oligoclonal expansion of (CAR) T-cells as a potential contributing pathomechanism of severe CAR-T hematotoxicity is finally out in @BloodJournal! Fantastic transatlantic collab with Young lab @nih_nhlbi ! Tweetorial ⬇️
ashpublications.org
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for...
TO THE EDITOR:
Kai Rejeski
@KRejeski
Apr 20, 2023
What mechanisms determine resistance to CAR-T therapy and how can we treat relapse in LBCL and Multiple Myeloma? Check out our new review @ASTCT_Journal !
Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell...
From astctjournal.org
9.6K
Kai Rejeski
@KRejeski
Sep 22, 2023
Are all cytopenias after CAR-T created equal? We explored that question using the phenotypes of post-CAR neutrophil recovery as a blueprint to examine the pathophysiology of hematotoxicity and study its prognostic impact. Out today @ScienceAdvances 🎉
science.org
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation...
Post CAR-T neutrophil recovery phenotypes impact survival and reflect CAR expansion kinetics and serum proteomic changes.
19K
Kai Rejeski
@KRejeski
Jun 26, 2023
In other life news.. She said yes! 💍 #somewhereinsouthernfrance
14K
Kai Rejeski
@KRejeski
Jun 10, 2023
Real honor to present our consensus grading and best practice recommendations for immune effector cell-associated hematotoxicity (ICAHT) on behalf of @EHA_Hematology and @TheEBMT and entire team today at #EHA23! Manuscript out in parallel @BloodJournal
ashpublications.org
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice...
Distinct patterns of cytopenias that are distinguishable from standard chemotherapy-associated cytopenias are seen after chimeric antigen receptor T-cell t
23K
Kai Rejeski
@KRejeski
Oct 5, 2023
About yesterday. #newlyweds #celebratingtogether 🎉
7.8K
Kai Rejeski
@KRejeski
Nov 6, 2022
Happy to present four abstracts at #ASH22 this year! Let me share our results on markers of CAR-T immunotoxicity and response 1️⃣ we present the HT10 score as a tool to discriminate between early infections and CRS - now externally validated! ash.confex.com/ash/2022/webpr…
Kai Rejeski
@KRejeski
Nov 2, 2023
Couldn’t be more excited to join @MSKCancerCenter as a visiting investigator in #bmt #celltx ! Particularly excited to hone my computational skills learning from the amazing @RShouval and to train under @DrMiguelPerales and others :) #computationalimmunology #CART #toxicity
11K
Kai Rejeski
@KRejeski
Sep 7, 2023
Great to see our @EHA_Hematology and @TheEBMT consensus guidelines article on immune effector cell-associated hematotoxicity out in full print in @BloodJournal ! 🎉🎉🎉 Very proud of this European team effort!
ashpublications.org
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice...
Distinct patterns of cytopenias that are distinguishable from standard chemotherapy-associated cytopenias are seen after chimeric antigen receptor T-cell t
5.3K
Kai Rejeski
@KRejeski
Apr 6, 2023
Can we identify early infections in the setting of CRS after CD19 CAR-T therapy for r/r B-NHL? Check out our new paper addressing this question out today in @Hemasphere_EHA! Tweetorial 👇 journals.lww.com/hemasphere/Ful…
16K
Kai Rejeski
@KRejeski
Oct 15, 2023
Very happy to receive the Young Investigator Award from the @dgho_eV at #DGHO2023 for our work on mechanisms of #ICAHT 🎉 Even better to receive the award directly from my mentor @MSubklewe ! Thanks to @LMU_HaemOnk @MCSP_LMU @BergweltMichael for the support in the last years!
5.6K
Kai Rejeski
@KRejeski
Nov 27, 2023
Very much looking forward to exciting CAR-T research at this years #ASH23 in San Diego. Come check out our oral presentation applying the @EHA_Hematology @TheEBMT grading for #ICAHT across #lymsm and #mmsm ash.confex.com/ash/2023/webpr… Grateful for the ASH achievement award 🙌
11K
Kai Rejeski
@KRejeski
Nov 18, 2023
Powerhouse work by @ErikaKampouri and @JoshuaHillMD outlining risk factors of CMV reactivation after CAR-T 👍 Beware in patients receiving BCMA directed CART and with extended corticosteroid use 👆 #CARTID
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen...
From academic.oup.com
8K